HC Wainwright Reaffirms "Buy" Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

HC Wainwright restated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR - Free Report) in a research report released on Friday morning,Benzinga reports. The firm currently has a $80.00 target price on the biotechnology company's stock.

Several other equities analysts have also recently issued reports on ARWR. Citigroup decreased their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating for the company in a research note on Wednesday, November 27th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday. Sanford C. Bernstein decreased their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a research report on Friday, November 29th. Finally, Chardan Capital reissued a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.70.

Arrowhead Pharmaceuticals Trading Down 0.3 %

Shares of ARWR stock traded down $0.05 on Friday, hitting $19.45. The stock had a trading volume of 4,010,988 shares, compared to its average volume of 1,283,558. The company's 50 day moving average price is $21.23 and its 200-day moving average price is $23.09. Arrowhead Pharmaceuticals has a 1 year low of $17.05 and a 1 year high of $39.83. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The firm has a market capitalization of $2.42 billion, a P/E ratio of -3.87 and a beta of 0.91.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 26,712 shares of the company's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $21.24, for a total transaction of $567,362.88. Following the completion of the sale, the chief executive officer now directly owns 3,688,335 shares of the company's stock, valued at $78,340,235.40. This represents a 0.72 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William D. Waddill sold 3,748 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $21.90, for a total value of $82,081.20. Following the completion of the transaction, the director now owns 44,125 shares in the company, valued at $966,337.50. This trade represents a 7.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently modified their holdings of ARWR. Fifth Third Bancorp lifted its stake in shares of Arrowhead Pharmaceuticals by 42.5% in the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 354 shares during the period. Values First Advisors Inc. purchased a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $52,000. Meeder Asset Management Inc. increased its position in Arrowhead Pharmaceuticals by 4,629.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company's stock worth $88,000 after purchasing an additional 3,333 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company's stock worth $88,000 after buying an additional 788 shares in the last quarter. Finally, nVerses Capital LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $96,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.